Status:
UNKNOWN
Safety and Efficacy of the Novel Selective Nicotinic Receptor Partial Agonist, CHANTIX (Varenicline) in Patients With Acute Coronary Syndrome
Lead Sponsor:
Newark Beth Israel Medical Center
Conditions:
Smoking
Acute Coronary Syndrome
Eligibility:
All Genders
18+ years
Phase:
PHASE4
Brief Summary
Assess the role of a nicotine antagonist in helping patients presenting to hospital with acute coronary syndrome to stop smoking.
Eligibility Criteria
Inclusion
- active smokers presenting to hospital with an acute coronary syndrome
Exclusion
- patients with an acute coronary syndrome who are not active smokers
Key Trial Info
Start Date :
January 1 2008
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
Estimated Enrollment :
100 Patients enrolled
Trial Details
Trial ID
NCT01170338
Start Date
January 1 2008
Last Update
July 27 2010
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Newark Beth Israel Medical Center
Newark, New Jersey, United States, 07112